Key facts
- This page summarizes John A. Fallon MD's Form 4 filing for COLLEGIUM PHARMACEUTICAL, INC (COLL).
- 5 reported transactions and 2 derivative rows are listed below.
- Accepted by SEC: 14 Nov 2025, 16:10.
John A. Fallon MD - 12 Nov 2025 Form 4 Insider Report for COLLEGIUM PHARMACEUTICAL, INC (COLL)
- Reporting relationship
- Director
- Issuer ticker
- COLL
- Reported as of
- 12 Nov 2025
- Net transaction value
- -$1,212,957
- SEC form
- 4
- Accepted by SEC
- 14 Nov 2025, 16:10:00 UTC
- Prior SEC filing
- 19 May 2025
- Source filing
- View source filing
- Reporting owner signature
- /s/ Colleen Tupper as Attorney-in-Fact for John A. Fallon, MD
Source evidence
Original filing metadata and source links for verification.
4 source fields
Reporting owner
1 detail
Key filing fact
John A. Fallon MD filed Form 4 for COLLEGIUM PHARMACEUTICAL, INC (COLL) on 14 Nov 2025.
Change
- Previous filing in this sequence was filed on 19 May 2025.
- Current net transaction value: -$1,212,957.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reporting Owners (1)
CIK 0001560152
Primary reporting owner
Fallon John A.
- Relationship
- Director
- Address
- C/O COLLEGIUM PHARMACEUTICAL, INC., 100 TECHNOLOGY CENTER DRIVE, STOUGHTON
- Signature
- /s/ Colleen Tupper as Attorney-in-Fact for John A. Fallon, MD
- Signature date
- 14 Nov 2025
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
COLL
transaction
Common Stock
Options Exercise
- Transaction value
- $247,350
- Shares
- +15,000
- Change %
- +23%
- Price
- $16.49
- Shares after
- 79,634
- Date
- 12 Nov 2025
- Ownership
- Direct
COLL
transaction
Common Stock
Options Exercise
- Transaction value
- $185,228
- Shares
- +19,853
- Change %
- +25%
- Price
- $9.33
- Shares after
- 99,487
- Date
- 12 Nov 2025
- Ownership
- Direct
COLL
transaction
Common Stock
Sale
- Transaction value
- $1,645,536
- Shares
- -34,853
- Change %
- -35%
- Price
- $47.21
- Shares after
- 64,634
- Date
- 12 Nov 2025
- Ownership
- Direct
- Footnotes
- F1
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
COLL
transaction
Derivative
Stock Option (Right to Purchase)
Options Exercise
- Transaction value
- $0
- Shares
- -15,000
- Change %
- -100%
- Price
- $0.000000
- Shares after
- 0
- Date
- 12 Nov 2025
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 15,000
- Exercise price
- $16.49
- Footnotes
- F2
COLL
transaction
Derivative
Stock Option (Right to Purchase)
Options Exercise
- Transaction value
- $0
- Shares
- -19,853
- Change %
- -100%
- Price
- $0.000000
- Shares after
- 0
- Date
- 12 Nov 2025
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 19,853
- Exercise price
- $9.33
- Footnotes
- F2
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 2 footnotes
Footnote F1
The price reported in column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $46.805 to $47.51, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the U.S. Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
Footnote F2
The option is fully vested and exercisable.